Overview


According to FutureWise analysis the market for Antibacterial Drug Resistance in 2023 is US$ 10.66 billion, and is expected to reach US$ 16.38 billion by 2031 at a CAGR of 5.52%.

Antibacterial drug resistance, also known as antibiotic resistance, pertains to the capacity of bacteria to adapt and evolve in manners that diminish the effectiveness or render ineffective antibiotics in treating bacterial infections. This occurs due to the selective pressure imposed by the overuse and misuse of antibiotics, which drives the survival and proliferation of bacteria that have acquired resistance mechanisms. These mechanisms can be genetic mutations or obtained from other bacteria through processes like horizontal gene transfer. 

As bacteria develop resistance, commonly used antibiotics lose their ability to eradicate or control bacterial infections, leading to prolonged illnesses, increased healthcare costs, and elevated mortality rates. Conditions like urinary tract infections or pneumonia, previously easily manageable, now present more significant treatment challenges, potentially resulting in more severe consequences. The consequences of antibacterial drug resistance are far-reaching. Prolonged hospital stays become more common, putting additional strain on healthcare systems. Medical costs escalate due to the need for more expensive and potent antibiotics and extended treatment durations. 

FutureWise Market Research has published a report that provides an insightful analysis of Antibacterial Drug Resistance Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts' projects that the Antibacterial Drug Resistance Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.

  • Melinta Therapeutics
  • Allergan
  • Merck
  • Abbott Laboratories
  • Pfizer
  • GSK
  • PENDOPHARM
  • Absynth Biologics
  • Achaogen
  • Acino Holdings
  • Aventis Pharma
  • Austell Laboratories
  • Assembly Biosciences
  • Arpida
  • Demuris
  • Evolva Holding
  • ContraFect

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in the Antibacterial Drug Resistance Market:

  • In January 2023, Alkem Laboratories introduced Zidavi, an antibiotic designed to combat multiple drug-resistant (MDR) infections. This medication combines avibactam and ceftazidime and manages diverse conditions, including complex urinary tract infections (cUTI). Additionally, Zidavi has garnered approval from regulatory bodies such as the U.S. FDA, EMEA, and CDSCO for treating complicated intra-abdominal infections (IAIs) and hospital-acquired pneumonia (HAP), offering an alternative to colistin and meropenem.

Overuse and misuse of antibiotics in the healthcare setting contribute significantly to the development of drug resistance, which is driving the market. Increased healthcare infrastructure with expanded healthcare expenditure enhances market growth. International trade and travel facilitate the rapid spread of resistant bacteria across the globe, making it harder to contain outbreaks, hence driving the market. Inadequate hygiene practices in healthcare settings and poor sanitation and hygiene in the communities contribute to spreading resistant bacteria and infections, propelling the market. In addition, government initiatives are taken to raise awareness and funds given by the government and non-government bodies for research and development to launch more innovative and new drugs to work efficiently and provide better treatment outcomes, hence bolstering the market.
However, significant barriers affect the market growth, such as the implementation of strict policies and regulations for antibiotics use in healthcare, agriculture, and veterinary medicine, often challenging the market growth. Advancements in technology can enable targeted antibiotic use, ensuring that these drugs can only be prescribed when necessary, restraining the market growth.

By Type

  • Telavancin (Vibativ)
  • Ceftaroline Fosamil (Teflaro/ Zinforo)
  • Fidaxomicin (Dificid / Dificlir)
  • Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
  • Dalbavancin (Dalvance/ Xydalba)
  • Tedizolid Phosphate (Sivextro)
  • Oritavancin (Orbactiv/ Nuvocid)
  • Ceftolozane-Tazobactam (Zerbaxa)
  • Ceftazidime-Avibactam (Avycaz/ Zavicefta)
  • PHASE III DRUGS

By Application

  • Complicated Urinary Tract Infection (CUTI)
  • Complicated Intra-Abdominal Infections (CIAI)
  • Blood Stream Infections (BSI)
  • Clostridium Difficile Infections (CDI)
  • Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
  • Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
  • Community Acquired Bacterial Pneumonia (CABP)

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of the region will also be provided in the final version of this market, which is based on the conclusion of primary interviews and secondary data points gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 due to the high burden of antibiotic resistance gram-negative infections, new launches to address drug resistance, expanded healthcare infrastructure, increase in healthcare expenditure, government initiatives taken in edition two aware the patients contributing to the market growth in this region.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the of Antibacterial Drug Resistance Market By Type, By Application and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections, which are represented in the format of data sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors, which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Antibacterial Drug Resistance Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Type Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antibacterial Drug Resistance Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Antibacterial Drug Resistance Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Type Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Type Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Antibacterial Drug Resistance Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Telavancin (Vibativ)
        2. Ceftaroline Fosamil (Teflaro/ Zinforo)
        3. Fidaxomicin (Dificid / Dificlir)
        4. Ceftobiprole Medocaril (Zevtera/ Zeftera/ Mabelio)
        5. Dalbavancin (Dalvance/ Xydalba)
        6. Tedizolid Phosphate (Sivextro)
        7. Oritavancin (Orbactiv/ Nuvocid)
        8. Ceftolozane-Tazobactam (Zerbaxa)
        9. Ceftazidime-Avibactam (Avycaz/ Zavicefta)
        10. PHASE III DRUGS.

  • 8.   Antibacterial Drug Resistance Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Complicated Urinary Tract Infection (CUTI)
        2. Complicated Intra-Abdominal Infections (CIAI)
        3. Blood Stream Infections (BSI)
        4. Clostridium Difficile Infections (CDI)
        5. Acute Bacterial Skin And Skin Structure Infections (ABSSSI)
        6. Hospital Acquired Bacterial Pneumonia/Ventilator (HABP/VABP)
        7. Community Acquired Bacterial Pneumonia (CABP)

  • 9.   North America Antibacterial Drug Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 10.   Latin America Antibacterial Drug Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 11.   Europe Antibacterial Drug Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 12.   Asia Pacific Antibacterial Drug Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 13.   Middle East and Africa Antibacterial Drug Resistance Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 14.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Melinta Therapeutics
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Allergan
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Merck
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Abbott Laboratories
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. GSK
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. PENDOPHARM
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Absynth Biologics
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Achaogen
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Acino Holdings
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Aventis Pharma
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Austell Laboratories
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Assembly Biosciences
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Arpida
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Demuris
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Evolva Holding
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. ContraFect
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client

Related Market

Antibacterial Drugs Market

Read More
Partner

Our Clients